论文部分内容阅读
目的探讨伊马替尼联合干扰素-α在慢性髓性白血病中的治疗效果。方法 50例已确诊的慢性髓性白血病患者,随机分为观察组和对照组,各25例。观察组给予伊马替尼和干扰素-α联合治疗;对照组给予伊马替尼治疗。观察两组患者治疗后的细胞遗传学反应状况,根据细胞遗传学反应情况对患者进行疗效评定。观察两组患者治疗过程中的不良反应。结果观察组微小细胞遗传学反应(MCR)+部分细胞遗传学反应(PCR)+完全细胞遗传学反应(CCR)所占比例所占比例高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论伊马替尼联合干扰素-α在慢性髓性白血病中的治疗效果显著,干扰素-α有助于提高治疗效果,同时有助于减少不良反应发生,值得借鉴。
Objective To investigate the therapeutic effect of imatinib combined with interferon-α in chronic myeloid leukemia. Methods Fifty patients with chronic myeloid leukemia who had been diagnosed were randomly divided into observation group and control group, with 25 cases each. The observation group was treated with imatinib and interferon-α, while the control group was given imatinib. After treatment, the cytogenetic response of the two groups was observed, and the curative effect was evaluated according to the cytogenetic response. Adverse reactions in the two groups were observed. Results The proportions of MCR, PCR and CCR in the observation group were higher than those in the control group (P <0.05) . The incidence of adverse reactions in the observation group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Imatinib combined with interferon-α in the treatment of chronic myeloid leukemia effect is significant, interferon-α can help to improve the therapeutic effect, and help reduce the incidence of adverse reactions, is worth learning from.